Calvert inks deal with Particle Sciences on early-stage development

Toxicology specialist Calvert Labs is joining forces with the formulation experts at Particle Sciences to offer an early-stage service package designed to speed up drug development.

The collaboration tasks Particle with developing a drug formulation designed to meet specific exposure levels, and then Calvert will come in to carry out toxicology testing, removing much of the guesswork sponsors face when outsourcing the two processes to different providers, the companies said.

Calvert has been in the toxicology testing business for more than 40 years, offering services from candidate identification to IND-focused tests, and CEO Charles Spainhour said allying with Particle will help solve what is often a major obstacle for the company's clients.

Particle bills itself as a world leader in nano-milling and lipidic formulation technologies, and combining its services with Calvert will help it woo customers with a unique offering in the industry, CEO Mark Mitchnick said.

"No single group has the in-depth expertise in both formulation and toxicology needed to tackle this," Mitchnick said in a statement. "Through this combined effort, under a single scope of work, our clients are getting a very valuable service unavailable anywhere else."

- read the announcement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.